NAUT

Nautilus Biotechnology Inc

NASDAQ: NAUT · HEALTHCARE · BIOTECHNOLOGY

$2.93

-10.82% today

Updated 2026-06-05

Market cap

$347.56M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.46

Dividend yield

—

52W range

$1 – $4

Volume

0.4M

Market cap

$347.56M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.46

Dividend yield

—

52W range

$1 – $4

Volume

0.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-0.1

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$4.00

+36.52%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.20x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -0.08 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-13.61M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-57.92M	$-63.67M	$-70.78M	$-59.00M	$-14.70M
EPS	—	—	—	—	$-0.46
Free cash flow	$-48.13M	$-54.15M	$-61.27M	$-51.97M	$-13.61M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-04	PATEL, SUJAL M	Buy	25,000	$2.61
2026-03-02	WELD, GWEN E	Buy	160,000	—
2026-03-02	SUZUKI, KENTARO	Buy	160,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NAUT	$347.56M	25	4.3	3.0	5.0	6.0	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Nautilus Biotechnology Inc trades at $2.93. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -0.08, it sits in the distress.

Frequently asked questions

What is Nautilus Biotechnology Inc's stock price?

Nautilus Biotechnology Inc (NAUT) trades at $2.93.

Is Nautilus Biotechnology Inc overvalued?

Nautilus Biotechnology Inc carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Nautilus Biotechnology Inc (NAUT)?

The 12-month analyst consensus target is $4.00, about 36.5% above the current $2.93. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Nautilus Biotechnology Inc's Altman Z-Score is -0.08, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-39.53%

Beta0.75

50D MA$2.94

200D MA$1.98

Shares out0.13B

Float0.05B

Short ratio—

Avg volume0.4M

Performance

1 week-8.02%

1 month+32.75%

3 months+47.57%

YTD+55.90%

1 year—

3 years—

5 years—

Compare

NAUT vs LLY →NAUT vs JNJ →NAUT vs ABBV →Stock screener →